RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer

Jie Li, Zhongqiu Zhang, Zunyan Dait, Anthony P. Popkie, Christoph Plass, Carl Morrison, Yian Wang, Ming You

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


In the present studies, we investigated the correlation between RASSF1A promoter methylation status and Kras2 mutations in 65 primary non small cell lung cancer (NSCLC) including 33 adenocarcinomas, 12 large cell carcinomas, and 20 squamous cell carcinomas. Mutational analysis of Kras2 showed: 30% (10 of 33) of adenocarcinomas, 25% (3 of 12) of large cell carcinomas, and only 5% (1 of 20) of squamous cell carcinomas contained activated Kras2 mutation at codon 12 or 13. RASSF1A promoter region CpG island methylation was detected in adenocarcinomas (55%), large cell carcinomas (25%), and squamous cell carcinomas (25%). Interestingly, combined RASSF1A methylation and Kras2 mutation data show that only ∼7% adenocarcinomas/large cell carcinomas exhibited both KRASSF1A promoter methylation and Kras2 mutation, whereas 24% adenocarcinomas, 50% large cell carcinomas, and 70% squamous cell carcinomas showed neither Kras2 mutation nor RASSF1A promoter methylation. These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inactivation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas. Our results indicate a trend of inverse relationship between Kras2 activation and RASSF1A promoter methylation in the majority of human lung adenocarcinomas and large cell carcinomas.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
Issue number4
StatePublished - 2003


  • Kras2
  • Lung cancer
  • Methylation
  • Mutations

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer'. Together they form a unique fingerprint.

Cite this